Synergistic prognostication of left ventricular hypertrophy and three-dimensional mechanical dyssynchrony in heart

Takahiro Doi1, Tomoaki Nakata2, Satoshi Yuda3

  • 1Department of Cardiology, Teine-Keijinkai General Hospital, Sapporo, Japan.

ESC Heart Failure
|January 23, 2020
PubMed

Insights

Left ventricular mechanical dyssynchrony (LVMD) and hypertrophy (LVMI) are independent predictors of cardiac events in heart failure (HF) patients. Combining these measures improves risk stratification beyond traditional clinical parameters.

Area of Science:

  • Cardiology
  • Medical Imaging
  • Heart Failure Research

Background:

  • Chronic systolic heart failure (HF) poses significant mortality risks.
  • Left ventricular hypertrophy (LVMI) and mechanical dyssynchrony (LVMD) are known contributors to HF progression.
  • Gated myocardial perfusion imaging (MPI) offers a 3D assessment of cardiac function.

Purpose of the Study:

  • To investigate the prognostic significance of LVMD and LVMI in patients with chronic systolic HF.
  • To evaluate the combined predictive value of LVMD and LVMI for lethal cardiac events (CE).
  • To determine if these parameters improve risk stratification compared to conventional clinical factors.

Main Methods:

  • 829 HF patients with reduced ejection fraction underwent gated MPI for 3D LVMD assessment (phase SD).
  • LVMI was measured using Corridor 4DM software.
  • Patients were followed for a mean of 34 months to document CE.

Main Results:

  • The CE group exhibited significantly higher phase SD and LVMI compared to the non-CE group.
  • Optimal cut-off values identified were phase SD > 37 and LVMI > 122.7 g/m².
  • Patients with both elevated phase SD and LVMI had the highest CE rate (P < 0.0001).
  • Phase SD and LVMI were independent predictors of CE (HR 1.038 and 1.005, respectively).
  • Incorporating phase SD and LVMI improved prognostic value incrementally over clinical parameters like age, NYHA class, eGFR, and BNP.

Conclusions:

  • Three-dimensionally assessed LVMD is an independent prognostic marker in chronic HF.
  • LVMI also demonstrates independent prognostic value in HF patients.
  • The combination of LVMD and LVMI significantly enhances risk stratification for chronic HF patients, synergistically with conventional clinical parameters.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
607
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
310
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
315
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
255
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
383